Med-Tech is at the forefront of all new treatments and standard of care regarding the medical segment of BHRT, Peptides and all new compounding pharmacy medications. Med-Tech uses the standards set forth by the American Urology Association, American Endocrinology Association, along with all REMS (Risk Evaluation and Mitigation Strategies) set-forth from the FDA whenever a new medication is brought to market. We stay on top of these changes in the law and landscape to make sure your practice stays in compliance regarding new policies and procedures.